Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark

Trine Trab, Iman Chanchiri, Ahmed Al-Mashhadi, Emma Berggreen Dall, Stine Rasch, Mette Johansen, Simon Husby, Michael Roost Clausen, Thomas Stauffer Larsen, Andriette C Desseau-Arp, Jacob Haaber Christensen, Robert Schou Pedersen, Mikael Frederiksen, Peter de Nully Brown, Tarec Christoffer El-Galaly, Kirsten Gronbaek

Blood (2024) 144 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2024-201293

Published: 2024

Journal Articles

Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group

Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric, Mikkel Runason Simonsen, Michael Roost Clausen, Ahmed Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Anne Ortved Gang, Peter Brown, Tarec Christoffer Christoffer El-Galaly, Thomas Stauffer Larsen

Blood (2024) 144 (Supplement 1): 650.

https://doi.org/10.1182/blood-2024-201672

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Raul Cordoba, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Toshihiko Oki, Andrew J. Steele, Yi Hao, Kimberly G. Archer, Ali Rana, David Belada

Blood (2024) 144 (Supplement 1): 581.

https://doi.org/10.1182/blood-2024-198023

Published: 2024

Journal Articles

Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial

Yasmin H. Karimi, Michael Roost Clausen, David John Lewis, Wojciech Jurczak, Michelle Poon, Tae Min Kim, Young Rok Do, Pieternella Lugtenburg, Kristin Conte, David Soong, Barbara D'Angelo Månsson, Zhu Li, Christian Eskelund, Martin Hutchings

Blood (2024) 144 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2024-199225

Published: 2024

Journal Articles

NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Emil Ramsø Kyvsgaard, Morten Grauslund, Lene Sjö, Linea Melchior, Trine Grantzau, Lise Mette Gjerdrum, Trine Trab, Lærke Sloth Andersen, Anne Ortved Gang, Marie Fredslund Breinholt, Michael Boe Møller, Jacob Haaber Christensen, Thomas Stauffer Larsen, Michael Roost Clausen, Anna Caroline Hasselbalch Riley, Carsten Utoft Niemann, Kirsten Gronbaek, Martin Hutchings, Simon Husby

Blood (2024) 144 (Supplement 1): 1594.

https://doi.org/10.1182/blood-2024-204772

Published: 2024

Journal Articles

Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)

Tycel J. Phillips, Michael Roost Clausen, Wojciech Jurczak, Tae Min Kim, Kim Linton, Chan Y Cheah, Jieying Jiang, Kubra Karagoz, Mohammad Atiya, Christian Eskelund, Han Si, Edith Szafer Glusman, Andrew J. Steele, Charles Kearns, Catherine Thieblemont

Blood (2024) 144 (Supplement 1): 3115.

https://doi.org/10.1182/blood-2024-199799

Published: 2024

Journal Articles

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4480.

https://doi.org/10.1182/blood-2024-198714

Published: 2024

Journal Articles

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Catherine Thieblemont, Yasmin H. Karimi, Chan Y Cheah, Michael Roost Clausen, Kim Linton, Tycel J. Phillips, Franck Morschhauser, Martin Hutchings, Rebekah Conlon, Saurabh Mukhopadhyay, Aurelie Le Maitre, Yu Deng, Mariana Sacchi, Thomas Doerr, Minh Dinh, William Palo, Loretta Nastoupil

Blood (2024) 144 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2024-200957

Published: 2024

Journal Articles

Differences in Overall Survival for Non-Western Immigrant Patients Compared to Danish-Born Patients with Diffuse Large B-Cell Lymphoma

Mikkel Runason Simonsen, Lasse Hjort Jakobsen, Marianne Tang Severinsen, Henrik Frederiksen, Carsten Utoft Niemann, Judit Mészáros Joergensen, Michael Roost Clausen, Jørn Starklint, Søren Paaske Johnsen, Tarec Christoffer El-galaly, Joachim Baech

Blood (2023) 142 (Supplement 1): 6257.

https://doi.org/10.1182/blood-2023-179786

Published: 2023

Journal Articles

CD3xCD20 Bispecific Antibodies Yields Long-Term Survival in Relapsed/Refractory B Cell Lymphoma: A Follow-up Study of Patients Treated in Pivotal Phase 1/2 Trials

Emil Ramsø Kyvsgaard, Michael Roost Clausen, Anna Caroline Hasselbalch Riley, Carsten Utoft Niemann, Kirsten Grønbæk, Martin Hutchings, Simon Husby

Blood (2023) 142 (Supplement 1): 618.

https://doi.org/10.1182/blood-2023-178323

Published: 2023

Journal Articles

Low Mortality from COVID-19 Infection in Patients with B-Cell Lymphoma after Bispecific CD20xCD3 Therapy

Emil Ramsø Kyvsgaard, Anna Caroline Hasselbalch Riley, Michael Roost Clausen, Mads Harsløf, Line Dam Heftdal, Carsten Utoft Niemann, Kirsten Grønbæk, Martin Hutchings, Simon Husby

Blood (2023) 142 (Supplement 1): 4501.

https://doi.org/10.1182/blood-2023-178321

Published: 2023

Journal Articles

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Blood (2023) 142 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2023-173247

Published: 2023

Journal Articles

A Population-Based Study on Performance of Clinical Prognostic Models in Patients with Diffuse Large B-Cell Lymphoma Younger Than 70 Years

Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric, Michael Roost Clausen, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Peter de Nully Brown, Tarec Christoffer Christoffer El-Galaly, Thomas Stauffer Larsen

Blood (2023) 142 (Supplement 1): 190.

https://doi.org/10.1182/blood-2023-182606

Published: 2023

Journal Articles

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Blood (2023) 142 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2023-179887

Published: 2023

Journal Articles

Immunohistochemical Tumor Expression Predicts Response to CD3xCD20 Bispecific Antibodies in Patients with Relapsed/Refractory B Cell Lymphoma

Emil Ramsø Kyvsgaard, Michael Roost Clausen, Anna Caroline Hasselbalch Riley, Carsten Utoft Niemann, Lene Sjö, Kirsten Grønbæk, Martin Hutchings, Simon Husby

Blood (2023) 142 (Supplement 1): 6113.

https://doi.org/10.1182/blood-2023-178315

Published: 2023

Journal Articles

Outcome after 3 rd Line Treatment for Diffuse Large B-Cell Lymphoma: A Danish Population-Based Study

Blood (2022) 140 (Supplement 1): 6706–6707.

https://doi.org/10.1182/blood-2022-167897

Published: 2022

Journal Articles

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 2292–2295.

https://doi.org/10.1182/blood-2022-157194

Published: 2022

Journal Articles

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 9443–9445.

https://doi.org/10.1182/blood-2022-158245

Published: 2022

Journal Articles

Impact of Trial Eligibility Criteria on Outcomes of 1,245 Patients with Follicular Lymphoma Treated in the Real-World Setting: A Danish Population-Based Study

Tine Bennedsen, Mikkel Simonsen, Peter de Nully Brown, Michael Roost Clausen, Andriette Dessau-Arp, Judit Jørgensen, Thomas S. Larsen, Christian Bjørn Poulsen, Lasse Hjort Jakobsen, Tarec Christoffer Christoffer El-Galaly

Blood (2022) 140 (Supplement 1): 3612–3614.

https://doi.org/10.1182/blood-2022-156376

Published: 2022

Journal Articles

Risk of Incident Diabetes and Dysregulated Pre-Existing Diabetes Mellitus in Newly Diagnosed Lymphoma Patients Treated with Steroid-Containing Immunochemotherapy: A Danish Population-Based Study

Joachim Baech, Marianne Tang Severinsen, Andreas Kiesbye Øvlisen, Henrik Frederiksen, Peter Vestergaard, Christian Torp-Pedersen, Judit M. Jørgensen, Michael Roost Clausen, Christian Bjørn Poulsen, Peter de Nully Brown, Anne Ortved Gang, Robert Schou Pedersen, Karin Ekstroem Smedby, Sandra Eloranta, Lasse H. Jakobsen, Tarec Christoffer El-Galaly

Blood (2021) 138 (Supplement 1): 454.

https://doi.org/10.1182/blood-2021-144733

Published: 2021

NARROW

Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark

Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group

Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial

NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Differences in Overall Survival for Non-Western Immigrant Patients Compared to Danish-Born Patients with Diffuse Large B-Cell Lymphoma

CD3xCD20 Bispecific Antibodies Yields Long-Term Survival in Relapsed/Refractory B Cell Lymphoma: A Follow-up Study of Patients Treated in Pivotal Phase 1/2 Trials

Low Mortality from COVID-19 Infection in Patients with B-Cell Lymphoma after Bispecific CD20xCD3 Therapy

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

A Population-Based Study on Performance of Clinical Prognostic Models in Patients with Diffuse Large B-Cell Lymphoma Younger Than 70 Years

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Immunohistochemical Tumor Expression Predicts Response to CD3xCD20 Bispecific Antibodies in Patients with Relapsed/Refractory B Cell Lymphoma

Outcome after 3 rd Line Treatment for Diffuse Large B-Cell Lymphoma: A Danish Population-Based Study

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Impact of Trial Eligibility Criteria on Outcomes of 1,245 Patients with Follicular Lymphoma Treated in the Real-World Setting: A Danish Population-Based Study

Risk of Incident Diabetes and Dysregulated Pre-Existing Diabetes Mellitus in Newly Diagnosed Lymphoma Patients Treated with Steroid-Containing Immunochemotherapy: A Danish Population-Based Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only